Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind randomized phase III study of lenalidomide maintenance after R-CHOP in diffuse large B-cell lymphoma
2008-008202-52Phase 3Completed
- Sponsor
- LYSARC
- Start
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diffuse large B-cell lymphoma (DLBCL) comparing Lenalidomide maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-free survival. Started Feb 2009; status: completed.
02
Drugs
lenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2008-008202-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008202-52.